• Anemias

Injectafer Generic Name & Formulations

General Description

Elemental iron (as ferric carboxymaltose) 50mg/mL; soln for IV inj; preservative-free.

Pharmacological Class


How Supplied

Single-dose vial (15mL)—1


Generic Availability


Injectafer Indications


Iron deficiency anemia (IDA) in patients ≥1yr of age who have intolerance or insufficient response to oral iron. In adults who have non-dialysis-dependent chronic kidney disease.

Injectafer Dosage and Administration

Adults and Children

<1yr: not established (IDA). Give by slow IV push (undiluted) at rate of approx. 100mg (2mL)/min; or by IV infusion (diluted) over 15mins. When giving via IV infusion, dilute to concentration not less than 2mg/mL of iron. ≥1yr (<50kg): 15mg/kg/dose in 2 doses separated by ≥7 days per course; (≥50kg): 750mg/dose in 2 doses separated by ≥7 days (total cumulative dose per course: 1500mg). For adults (≥50kg): alternatively can give 15mg/kg (up to max 1000mg) as a single-dose. May repeat treatment if IDA reoccurs.

Injectafer Contraindications

Not Applicable

Injectafer Boxed Warnings

Not Applicable

Injectafer Warnings/Precautions


Monitor for hypersensitivity reactions during and after administration for ≥30mins and until clinically stable. Have epinephrine inj immediately available. Possible risk for hypophosphatemia if history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, hyperparathyroidism, vitamin D deficiency, malnutrition. Monitor serum phosphate levels in at-risk patients who require a repeat course. Monitor for hypertension after each administration. Avoid extravasation. Neonates. Pregnancy (risk of fetal bradycardia esp. during 2nd & 3rd trimester). Nursing mothers.

Injectafer Pharmacokinetics

See Literature

Injectafer Interactions


Possible risk for hypophosphatemia with concurrent or prior use of drugs that affect proximal renal tubular function. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.

Injectafer Adverse Reactions

Adverse Reactions

Nausea, hypertension, flushing, hypophosphatemia, dizziness; rare: hypersensitivity reactions.

Injectafer Clinical Trials

See Literature

Injectafer Note

Not Applicable

Injectafer Patient Counseling

See Literature